RegCell secured $66 million to advance its regulatory T-cell immune tolerance platform, combining a fully subscribed $44 million Series A with a $22 million non-dilutive grant from Japan’s AMED. The financing positions the Nobel-winning technology for clinical translation. The structure of the round underscores continued reliance on national research funding alongside traditional venture capital for early translation in immune tolerance. Clinically, the focus is on moving regulatory T-cell approaches into patient studies where durable immune modulation is often the key differentiator.